RxDoctor Payments Data

Sara Thompson

Acute Care · Little Rock, ARNPI 1619216496

Payments from drug & device makers

$1,256in general payments, 2019–2025

Across 37 payments — averaging $33.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$748
  • Johnson & Johnson$135
  • Pfizer$111
  • Zimmer Biomet$87
  • Amgen$46
  • AstraZeneca$28
  • plus $102 from 6 others

What the payments were for

  • Food & beverage$1,256100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,256 in reported general payments places this provider in the 70th percentile of 321 acute care providers in Arkansas.

See all acute care providers in Arkansas

Medicare billing

Part B allowed, 2024
$126,805
Medicare patients
860
Services billed
3,412

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban274$225,277
XareltoRivaroxaban109$87,902
EntrestoSacubitril/Valsartan36$47,664
FarxigaDapagliflozin Propanediol35$22,956
Dofetilide113$13,087
JardianceEmpagliflozin17$9,748
MultaqDronedarone Hcl11$9,673
Metoprolol Succinate386$4,793
Atorvastatin Calcium396$3,870
Midodrine Hcl37$3,369
Ranolazine ErRanolazine26$3,181
Potassium Chloride200$2,899
Rosuvastatin Calcium160$2,143
Losartan Potassium243$1,874
Carvedilol294$1,774

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$111$225,277274 claims
Johnson & JohnsonXarelto$135$87,902109 claims
NovartisEntresto$17$47,66436 claims
AstraZenecaFarxiga$28$22,95635 claims
Sanofi-aventis U.S. LLCMultaq$22$9,67311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 321 acute care providers in Arkansas.

Other acute care in Little Rock

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →